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The objective of this investigation was to use a pharmacokinetic
(PK)/pharmacodynamic (PD) approach to describe and evaluate a PK model of nicotinic
acid (NiAc) in guinea pigs and a PD feedback model of changes in non-esterified fatty acid
(NEFA) concentrations in rats following multiple intravenous infusions of NiAc at different rates and durations of inhouse and literature (NEFA after extravascular NiAc dosing)
data. Serial arterial blood samples were taken for evaluation of NiAc exposure in guinea
pigs and NEFA in rats. The biophase kinetics of NiAc was assumed to impact on NEFA
turnover with feedback incorporated via an inhibitory moderator compartment. The
response acted linearly on the production of moderator, which then acted inversely on the
turnover rate of response. The potency, expressed as the amount of NiAc in the biophase
causing a 50 % inhibitory effect (ID50), was 6.5 nmol ± 31 % and the half-life of response
(t1/2, kout) 2 min ± 18 %. The half-life of tolerance (t1/2, ktol) was 9 min ± 27 %. The model can
be used to provide information about factors that determine the time course of NEFA
response following different rates and routes of administration of NiAc or NiAc analogues.

INTRODUCTION

The lipid-lowering effect of nicotinic acid (NiAc) was discovered by
Altschul et al. in 1955. NiAc inhibits lipolysis in adipose tissue, resulting in
a pronounced decrease in plasma concentrations of non-esterified fatty
acids (NEFA) (Carlson and Orö 1962, Carlson 1963). The decrease in
NEFA is followed by a decrease in triglyceride (TG), very-low-density
lipoprotein (VLDL) and low-density lipoprotein (LDL) plasma concentrations, and an increase in high-density lipoprotein (HDL) plasma
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concentrations. NiAc treatment has been associated with a decrease in
cardiovascular events such as myocardial infarction and death (Canner et
al. 1986, Carlson and Rosenhamer 1988, Carlson 2005) and to date is the
only approved drug that elevates HDL (Carlson 2005, Offermanns 2006).
In 2003, several groups reported that the G protein-coupled receptor
GPR109A (HM74A in humans; PUMA-G in mice) is activated by NiAc at
concentrations seen following therapeutic doses (Soga et al. 2003, Tunaru
et al. 2003, Wise et al. 2003). Binding of NiAc to the receptor in adipose
tissue starts a cascade of events (Fig. 1), which finally results in inhibition
of the breakdown of TG into NEFA and glycerol (Offermanns 2006).

FIGURE 1. Mechanism of NiAc-induced changes in lipid metabolism. Activation of the G proteincoupled receptor GPR109A by nicotinic acid (NiAc) results in inhibition of adenylyl cyclase (AC)
activity, leading to decreased formation of cyclic AMP (cAMP) from ATP. cAMP regulates lipolysis in
adipocytes by activating protein kinase A (PKA); in turn, PKA phosphorylates hormone-sensitive
lipase (HSL). The hydrolysis of triglycerides (TG) into non-esterified fatty acids (NEFA) and glycerol,
which is catalyzed by HSL, is thus reduced by NiAc.

Although, NiAc is an effective and unique hypolipemic agent, side
effects such as cutaneous vasodilatation evident as flushing, reduce its
therapeutic usefulness. Flushing accompanies pharmacologically active
doses and, like the hypolipemic effect, is mediated by activation of the
GPR109A receptor (Benyo et al. 2005). Furthermore, the time course of
NiAc-induced changes in plasma NEFA concentrations is complex. An
initial rapid drop in NEFA concentrations is followed by a rapid return
towards and above the predose baseline concentration, known as the
rebound effect. To improve the clinical benefit of NiAc, the
prostaglandin-induced flush and rebound of NEFA have to be addressed.
Characterizing the drug-induced pattern of NEFA response in terms
of modeling may enhance the understanding of its homeostatic control
mechanisms and the NiAc exposure-response relationships. These rela248
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tionships can be used for predicting the onset, intensity and duration of
response following different drug exposure scenarios. A quantitative
model describing the rate and extent of tolerance and rebound development may also guide for the medicinal chemistry program. A feedback
turnover model has proven to be flexible enough to capture the complex
time course of the NiAc-induced changes in plasma NEFA concentrations
including the subsequent rebound effect upon the rapid washout of NiAc
(Gabrielsson and Peletier 2008).
The primary aim of this study was to evaluate a series of in vivo experiments where NiAc had been given to guinea pigs and rats under different experimental conditions, and to develop a pharmacokinetic/pharmacodynamic (PK/PD) turnover model of the NiAc-induced
changes in NEFA plasma concentrations. The concentration-time relationship was studied in guinea pigs and the dose-response-time relationship was studied in rats. However, experiments were not originally
designed to support PK/PD modeling. Therefore, the presented datasets
may appear ‘patchy’, in that full exposure profiles of NiAc were not available from the rat studies on NEFA. Different strategies were followed to
resolve these shortcomings, A) High-dose pharmacokinetic data in rats
from the literature were used initially but failed (Iwaki et al. 1996), B)
Pharmacokinetic data from the inhouse guinea pig studies were scaled
allometrically to the rat. But, also this approach was unsuccessful, C) A
dose-response-time modeling approach succeeded in mimicking the
experimental NEFA data of the rat. The model was then challenged by literature data of NiAc-induced changes of plasma NEFA concentrations
after oral administration of test compound (Carballo-Jane et al. 2007).
Data were digitized and fitted by means of the proposed dose-responsetime model. The secondary aim was to make model simulations to estimate the pharmacological response at different steady-state plasma concentrations and to investigate the impact of tolerance.
MATERIALS & METHODS
Chemicals

Nicotinic acid (pyridine-3-carboxylic acid) was obtained from SigmaAldrich (St. Louis, MO, USA) and was dissolved in 0.9 % NaCl. All solvents were of analytical grade and the water used in the experiments was
obtained from a water purification system (Elgastat Maxima, ELGA, Lane
End, UK).
Analytical assays

Nicotinic acid analysis
Analysis was performed with hydrophilic interaction liquid chromatography (HILIC) and mass spectrometry detection using a triple
249
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quadrupole instrument with positive electrospray ionisation and Selected
Reaction Monitoring (SRM) acquisition. Plasma samples (50 µl/sample)
were precipitated with acetonitrile containing 0.2 % formic acid (150
µl/sample). After vortex mixing and centrifugation at 4 °C, an aliquot of
75 μl of the supernatant was diluted with 75 μl aqueous formic acid (0.2
%). Shimadzu LC-10AD vp pumps were used for gradient elution at 0.6
ml⋅min-1. The mobile phase consisted of (A) 2 % acetonitrile and 0.2 %
formic acid in water and (B) 0.2 % formic acid in acetonitrile. The separation was performed on a 50x2.1 mm Biobasic AX column with 5 μm
particles (Thermo Hypersil-Keystone, Runcorn,Cheshire, UK) with a gradient of 95 to 20 % B over 1 min, held at 20 % B for 1.5 min and returned
to initial conditions in one step. The front was diverted to waste.
Detection was performed by positive electrospray ionisation and SRM
acquisition with a Micromass Quattro Premier (Waters, Manchester, UK).
The mass transition was 124.0>80.2. The experimental parameters were
set as follows: capillary voltage 2 kV, source temperature 130 °C, desolvation temperature 400 °C, sample cone voltage 35 V, collision energy 17 eV
and argon collision gas flow 0.45 ml⋅min-1. Data acquisition and data evaluation were performed using MassLynx 4.0.
NEFA analysis
NEFA was analyzed in plasma using an enzymatic colorimetric
method (Wako Chemicals GmbH, Neuss, Germany) adapted to a 96-well
format. Ten µl of plasma was incubated with 80 µl of color reagent solution A (Acyl-CoA-Synthetase, Ascorbate oxidase, CoA, ATP, 4Aminophenazone and sodium Azide) at 37°C for 10 min, 150 µl of color
reagent solution B (Acyl-CoA-oxidase, Peroxidase and 3-Methyl-N-EthylN-(β-hydroxyethyl)aniline) was added, and the plate was incubated at
room temperature for 5-10 min. The plate was read at 550 nm
(Spectramax 340 PC, Molecular Devices).
Animals

In the pharmacokinetic studies, male guinea pigs (n=3; HB
Lidköpings Kaninfarm, Lidköping, Sweden), weighing 527–677 g, were
housed individually in a temperature- (20–22 °C) and humidity-controlled
(40–60 % relative humidity) facility with a 12:12-h light-dark cycle (lights
on 6:00 am). The animals had free access to chow (K1, Laktamin AB,
Stockholm, Sweden), hay and tap water until the day of the experiment.
In the pharmacodynamic studies, male Sprague Dawley rats (n=13, 10
in the treatment group (study 1-4) and 3 in the vehicle group (study 1);
Harlan Nederlands B.V.), weighing 383–447 g, were housed in pairs at a
room temperature of 20–22 °C and relative humidity of 40–60 % under a
12:12-h light-dark cycle (lights on 6:00 am). They had free access to standard rodent chow (R3, Laktamin AB, Stockholm, Sweden) and tap water.
250
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All experiments were carried out on anaesthetized animals and ethical permission was approved by the Local Ethics Review Committee on
Animal Experiments (Göteborg region).
Pharmacokinetics in guinea pig

Surgical procedures and experimental design
On the day of the experiment animals were fasted from 7:00 am. Two
hours later they were anaesthetized with an intraperitoneal injection of 66
mg⋅kg-1 pentobarbital (Apoteket AB, Sweden). The guinea pigs were tracheotomized with PE 240 tubing (Intramedic®, Becton Dickinson and
Company, USA) and connected to a small animal ventilator. One catheter
of PE 50 tubing (Intramedic®, Becton Dickinson and Company, USA) was
placed in a carotid artery for blood sampling and recording of arterial
blood pressure. Two catheters of PE 10 tubing (Intramedic®, Becton
Dickinson and Company, USA) were inserted into the jugular vein one for
infusion of NiAc or saline and the other for infusion of pentobarbital.
Blood gas was then analyzed (ABL 505, Radiometer, Copenhagen,
Denmark) and the ventilator adjusted to keep blood pH, pCO2 and pO2
within given reference ranges (7.44–7.50, 3.7–4.6 and 11–12, respectively).
During the experiment the animals received a constant infusion of pentobarbital (0.18 mg⋅min-1). A sterile sodium-citrate solution (Na3-citrate, 0.6
% w:v in sterile saline; Pharmaceutical and Analytical R&D, AstraZeneca,
Mölndal, Sweden) was used to prevent clotting in the catheters. Body temperature was monitored using a rectal thermocouple and maintained at 38
°C by means of external heating of an external heating lamp.
NiAc (4 mM dissolved in sterile 0.9 % NaCl) was given to each of 3
guinea pigs as 5 consecutive 20 min constant infusions, after each of which
the infusion rate was doubled (Table 1). Following the fifth infusion there
was a 40 min washout period, after which the protocol was repeated. Blood
samples (~120 µl) were collected prior to each change in NiAc infusion
rate and during both washout periods for subsequent analysis of NiAc
(Fig. 2). The samples were collected in EDTA-coated polyethylene tubes
and kept on ice until they were centrifuged (10 000 × g, 1 min, 4 °C).
The plasma was stored at –20 °C pending analysis.
TABLE 1. NiAc dosing regimens for the pharmacokinetic studies in guinea pigs
Dosing regimen

Animal 1
(0.527 kg)

Infusion rate
60.7, 121.45, 242.9, 485.8,
(nmol⋅kg-1⋅min-1)
971.5, 60.7, 121.45,
242.9, 485.8, 971.5
Length of infusion
(min)

20, 20, 20, 20,
20, 20, 20,
20, 20, 20

Animal 2
(0.677 kg)

Animal 3
(0.612 kg)

46.3, 92.9, 191.9, 378.2,
756.5, 47.3, 94.6,
189.1, 378.2, 756.5

52.3, 104.6, 209.2, 418.3,
836.6, 52.3, 104.6,
209.2, 418.3, 836.5

23.5, 17.8, 19.7, 19.5,
20, 20, 20,
20, 20, 20

20.5, 20, 20, 20,
20.5, 20, 20,
20.5, 19, 20
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Pharmacokinetic model of nicotinic acid in guinea pigs
A one-compartment infusion model (Eq. 1) was used for the pharmacokinetic analysis of NiAc concentration-time data from guinea pigs.

V⋅

dC p
dt

= Input − Cl ⋅ C p

(1)

where Cp is the plasma concentration of NiAc, Input is the dosing regimen
of NiAc, V is the volume of distribution and Cl clearance. A two-compartment model was also evaluated.
Pharmacodynamics in rat

Surgical procedures and experimental design
In order to characterize the complex drug-induced pattern in NEFA
response, changes in NEFA plasma concentrations following administration of NiAc were studied in 13 anaesthetized rats (referred to as studies
1 to 4), each of which employed a different constant intravenous dosing
regimen (Table 2).
TABLE 2. NiAc dosing regimens for the pharmacodynamic studies in rats
Dosing regimen

Intravenous Infusion
Rate (nmol⋅min-1)

Duration (min)
Total dose (mg·kg-1)
Oral Administration
Dose (µmol·kg-1)
(mg·kg-1)

Current Investigation

Carballo-Jane et al. (2007)

Study 1
n=10*

Study 2
n=1

Study 3
n=1

Study 4
n=1

0.8, 1.6, 3.2,
6.4, 12.8, 25.6

26

32, 64

30, 30, 30,
30, 30, 40
0.5

30

73, 31

0 → 13**
13
13 → 0**
30, 30, 30

0.2

1

0.2
24, 81, 810, 2400
3, 10, 100, 300

* n=7 in the treatment group and n=3 in the control group of Study 1
** 3 min stepwise rate changes

The surgery and handling of the animals before, during and after surgery were similar in all four studies. On the day before the experiment,
the rats received 6 g of standard rodent chow (R3) at 3:30 pm. At 7:00 am
on the experimental day they were weighed individually and moved to
clean cages without food. At 9:00 am they were anaesthetized with an
intra-peritoneal injection of Na-thiobutabarbital (Inactin®, Sigma
Chemical Co., St Louis, MO, USA), 180 mg·kg-1 BW. The rats were tracheotomized with PE 240 tubing (Intramedic®, Becton Dickinson and
252
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Company, USA) and allowed to breathe spontaneously. One catheter (PE
50 tubing; Intramedic®, Becton Dickinson and Company, USA) was
placed in a carotid artery for blood sampling and recording of arterial
blood pressure. Two catheters (PE 10 tubing; Intramedic®, Becton
Dickinson and Company, USA) were inserted into one jugular vein, one
for infusion of NiAc or vehicle and the other for infusion of diluted Nathiobutabarbital if the level of anesthesia had to be increased. A sterile
sodium-citrate solution (20.6 mM Na3-citrate in sterile saline;
Pharmaceutical and Analytical R&D, AstraZeneca, Mölndal, Sweden) was
used to prevent clotting in the catheters. Body temperature was monitored using a rectal thermocouple and maintained at 37.5 °C by means of
an external heating lamp. Blood pressure, heart rate and body temperature were continuously monitored (data not shown) on a custom-made
computerized recording system (Pharmlab, AstraZeneca R&D Mölndal,
Sweden). The animals were allowed a minimum post-surgical recovery
period of 1.5 h to enable glucose levels to stabilize.
NiAc dissolved in sterile 0.9 % NaCl was given to rats in four different
dosing regimens (Table 2), with the concentrations of the dosing solutions
being adjusted to give infusion flow rates in the range of 0.7 – 40 µl⋅min-1.
Three control animals were given the vehicle (sterile 0.9 % NaCl) in the
same dosing regimen as study 1. Following dosing there was a washout
period. Blood samples (~30 µl) were collected for analysis of NEFA predose, and during the infusions and washout period. The total sampled
blood volume per rat was 0.7 ml in study 1, 0.5 ml in study 2, 0.4 ml in
study 3 and 0.7 ml in study 4. The blood samples were collected in EDTAcoated tubes and kept on ice until they were centrifuged (10 000 × g, 1
min, 4 °C). The plasma was frozen at –20 °C pending analysis.
Pharmacodynamic model in rats
One set of pharmacological experiments was selected for the regression analysis. Because study 1 was the most informative experiment, containing several provocations of the system including a multiple stepwise
increase in NiAc infusion rate followed by a washout period and included the highest number of rats, the model was primarily built on this
experiment. It was then applied to the other three experiments.
Since no plasma concentrations of NiAc were available from the rat
experiments and applying the two-compartment model with parallel firstorder and Michaelis-Menten elimination proposed by Iwaki et al. (1996)
failed, a biophase kinetic model was applied with the turnover model.
The biophase kinetics of NiAc was modeled according to Equation 2:

dAb
= Input − ke ⋅ Ab
dt

(2)

where Ab, Input and ke are the drug amount in the biophase, the multiple
infusion regimen and the first-order elimination rate constant of NiAc in
253
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the biophase, respectively. Then the biophase kinetics of NiAc was
assumed to impact on NEFA turnover via an inhibitory Imax model, as
shown in Equation 3:

I max ⋅ Abn
I ( Ab ) = 1 − n
ID50 + Abn

(3)

Ab, Imax, ID50 and n are the drug amount in the biophase, efficacy (maximum drug-induced inhibitory effect of formation of response i.e. of the
NEFA response), potency (amount in biophase reducing the formation
of response by 50 %) and sigmoidicity factor, respectively. The mechanism of action of NiAc on NEFA plasma concentration (response R) is via
inhibition of turnover rate, as shown in Equation 4:

1
dR
= kin ⋅ ⋅ I ( Ab ) − kout ⋅ R
dt
M

(4)

where kin, M, kout and I(Ab) are the turnover rate, moderator, fractional
turnover rate and drug inhibitory function (Eq. 3), respectively. The
moderator M was assumed to inhibit the production of R, rather than
stimulating the loss of R. It is known from the literature (Frayn 2003) that
e.g. insulin, among other mechanisms of action, suppresses the formation of NEFA. The model aims at mimicking this process. The negative
feedback model whereby NiAc regulates NEFA metabolism is shown
schematically in Fig. 2.

FIGURE 2. Schematic illustration of the negative feedback model of NEFA metabolism in rats. The
biophase kinetics of NiAc acts on the production of NEFA (response R) via the inhibitory drug function I(Ab). R acts linearly on the production of the moderator M, which in turn acts inversely on the
production of R. Solid lines denote build-up and loss, and dashed lines indicate how the different
compartments influence each other.
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A change in R impacts on the moderator M via a first-order process ktol⋅R
(Eq. 5). The build-up and loss of M are governed by the first-order rate
constant for development of tolerance ktol.

dM
= ktol ⋅ ( R − M )
dt

(5)

The baseline is characterized by

dR
dM
= 0 and
=0
dt
dt

(6)

This means that for the baseline (R0, M0) there are two equations:

1
dR
= kin ⋅
− kout ⋅ R0 = 0
dt
M0

(7)

R0 = M 0

(8)

and

Solving for R0 and M0 yields

R0 = M 0 =

kin
kout

(9)

At steady state ss and taking account of the inhibitory function I ( Abss ) ,
Equation 9 becomes:

Rss =

kin
⋅ I ( Abss ) = R0 ⋅ I ( Abss )
kout

(10)

which is the relationship between R0 and Rss with drug present and in the
presence of moderator.
Initial parameter estimates of R0, kout and Imax were derived graphically according to Fig. 3 and Equations 9-15. The initial value of kout was estimated from the slope of the initial downswing of the response-time curve.
At a high dose, Ab exceeds ID50, and Equation 3 reduces to:

I ( Ab ) = 1 − I max

(11)

If we assume that Imax ≈ 1, then I(Ab) ≈ 0 and the term kin⋅1/M ⋅I(Ab) in
Equation 4 cancels out, giving the approximate first-order expression:

dR
≈ −kout ⋅ R
dt

(12)

A semi-logarithmic plot of R versus t gives a slope of -kout.

255
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The algebraic solution to the differential Equation 12, kout can be
expressed as:

kout = −

ln ( R1 ) − ln ( R2 )

(13)

t1 − t2

where R1, R2, t1 and t2 are the response at one time point, the response at
a second time point, and the two corresponding time points, respectively. The maximum decrease in NEFA Rmin at steady state is described by the
following expression, where Ab is assumed to be much greater than ID50:

Rmin ≈

kin
⋅ (1 − I max ) = R0 ⋅ 1 − I max
kout

(14)

The efficacy Imax is determined by using the Δ-response (Fig. 3), which is
the difference between the baseline R0 and the lowest observable steady
state response Rmin, according to:

(

Δ = R0 − Rmin = R0 − R0 ⋅ 1 − I max = R0 1 − 1 − I max

)

(15)

This equation can be rearranged and solved for Imax. The n parameter was
initially set to 2 and the ktol parameter was approximated to one half of
kout.
Because no drug concentration measurements were available in the
experiments where response was measured, the elimination rate constant
ke had to be estimated. The initial parameter estimate of ke was approximated from the guinea pig plasma concentration-time data scaled to rat.
From the data shown in Fig. 3, the time for half maximum response was
approximated to 35 min. By using the initial estimate of ke it was possible
to simulate Ab, hence determining the amount at 35 min. This was then
used as an initial estimate of ID50.

FIGURE 3. Schematic illustration of the rationale for estimating initial values of R0, kout and Δ.

256
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The initial estimate of volume of distribution was scaled from guinea
pig to rat. By using this scaled volume of distribution Vrat, the ID50 can be
converted to an IC50 value according to:
IC50 =

ID50
Vrat

(16)

The expression of Rss for a tolerant system (Eq. 10) can then be rewritten
as:

Rss = R0 ⋅ I (Css ) = R0 ⋅ 1 −

I max ⋅ C n
IC50n + C n

(17)

Removing the impact of the moderator compartment (feedback) results
in a non-tolerant system:

⎛
I ⋅Cn ⎞
Rssnotolerance = R0 ⋅ ⎜1 − max
⎟
n
n
⎝ IC50 + C ⎠

(18)

Two differential equations (Equations 4 and 5) were individually fitted to the response-time curve obtained from the different dosing scenarios using the Gauss-Newton (with the Levenberg and Hartley modification) algorithm of WinNonlin (version 4.1, Pharsight Corporation,
Palo Alto, CA, USA). A constant absolute error model was used for
weighting of data.
Analysis of literature data (Carballo-Jane et al. 2007)

In a recent study NiAc or vehicle was given as oral doses (vehicle, 3,
10, 30, 100 and 300 mg·kg-1) to conscious male Sprague Dawely rats
(n=30), and NEFA was measured at selected (20 min, and 1, 2 and 4 h
post-dose) time points in plasma (Carballo-Jane et al. 2007). In order to
quantitatively evaluate their data, the NEFA response time-courses from
the 3, 10, 100 and 300 mg·kg-1 doses were digitized. The relative (%)
NEFA values presented by Carballo-Jane et al. (2007) were recalculated
using a 0.5 mmol·l-1 baseline value. A first-order input-output biophase
model was used to drive the drug mechanism function of Equation 3. The
drug-mechanism function was then included in the turnover equation as
shown in Equation 19:

R
1
dR
= kin ⋅ ⋅ I ( Ab ) − kout ⋅ R ⋅ (1 − low )
dt
M
R

(19)

where Rlow is the physiological lower limit of the response.
The model parameters to be estimated were the first-order biophase
absorption rate constant Ka, the baseline value R0, the fractional turnover
rate kout, the rate constant of M·ktol and potency expressed as ID50.
The PK/PD turnover model, used in the previous analysis, was fitted
to the NEFA response time-courses of the 3, 10, 100 and 300 mg·kg-1
257
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doses, and the elimination rate constant ke was fixed to 0.4 min-1 according to our previously estimated values, and the bioavailability was assumed
to be equal to unity. Although high exposure to NiAc followed the higher doses, the NEFA concentrations were not reduced to zero. Therefore,
a physiological lower limit was included into the turnover model according to Yao et al. (2006).
RESULTS
Pharmacokinetics in guinea pig

Observed and predicted (one-compartment model) average plasma
concentrations of NiAc following consecutive infusions of NiAc are shown
in Fig. 4.

FIGURE 4. Plasma NiAc concentration–time profile in guinea pigs (n=3) after two intravenous infusion regimens each increasing every 20 min from 32, to 64, 128, 256 and finally 512 nmol⋅min-1. The
two incremental regimens were separated by a washout period of 40 min. The solid squares are the
mean observed concentrations, vertical lines show standard deviation, solid lines the average of three
model-predicted curves, and shaded areas the stepwise increases in NiAc infusion.

The exposure ranged between 0.05 and 17.5 µmol⋅l-1. The average
clearance was 70.5 ml⋅min-1⋅kg-1 ± 2.1 %, the average volume of distribution was 0.15 l⋅kg-1 ± 10.6 % and the average half-life was 1.5 min ± 10.2%,
respectively. The observed and predicted concentrations were consistent.
A two-compartment model was also fitted to the three individual concentration-time profiles. However, this analysis resulted in highly correlated parameters with poor precision. Even though the fit to the terminal
concentration-time points was better than analysis using the one-compartment model, the latter approach was preferred because the contribution of the terminal phase of the two-compartment model to the overall assessment of clearance and volume terms was negligible, as a conse258

https://scholarworks.umass.edu/dose_response/vol7/iss3/7

12

Isaksson et al.: Turnover modeling of non-esterified fatty acids in rats

Turnover modeling of non-esterified fatty acids in rats

quence of the plasma concentration falling more than two orders of magnitude within the first 15 min after stopping the infusion.
Pharmacodynamics in rat

The averaged plasma NEFA concentrations after administration of
NiAc (n=7) or vehicle (n=3) according to the dose regimen of study 1 are
shown in Fig. 5.

FIGURE 5. Time profiles of the plasma NEFA concentrations after intravenous administration of
NiAc ((black filled squares), n=7) or vehicle (0.9 % NaCl (gray filled squares), n=3) as six consecutive infusions of 0.8, 1.6, 3.2, 6.4, 12.8 and 25.6 nmol⋅min-1 with the infusion rate doubled every 30
min and stopped at 196 min. The break at 90 – 96 min was due to changing the syringe. Data are presented as mean, and vertical lines represent the standard deviation.

The observed and predicted pharmacological response, expressed as
changes in plasma NEFA concentrations, following different infusion regimens of NiAc (study 1, one individual rat) are shown in Fig. 6.
The predose baseline NEFA concentrations were 0.55 (average of 7
rats), 0.49, 0.34 and 0.43 mmol⋅l-1 in study 1 (n=7 (treated), n=3 (vehicle)), 2 (n=1), 3 (n=1) and 4 (n=1), respectively. In the vehicle group
(study 1) NEFA stayed constant throughout the experiment (gray symbols, Fig. 5). NiAc induced decreases in the plasma NEFA concentrations
to a minimum of 0.076 (average of 7 rats), 0.11, 0.058 and 0.14 mmol⋅l-1
in study 1 to 4, respectively. Relative to the predose baseline measurements the concentrations were reduced in the four studies by 86 % (average of 7 rats), 78 %, 83 % and 67 %, respectively. The NEFA concentrations at the peak of the rebound were, respectively, 0.76 (average of 7
rats), 0.84, 0.85 and 0.55 mmol⋅l-1, which corresponds to a 38, 71, 150 and
259
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FIGURE 6. Time course of observed (symbols) plasma NEFA concentrations (mmol⋅l-1) following
constant rate intravenous infusions of NiAc to male Sprague Dawely rats. NiAc administration commenced at t = 0 min. The solid black lines represent the effect predicted by the negative feedback
model. A) Study 1 - The fit of an individual rat treated with NiAc as six consecutive infusions of 0.8,
1.6, 3.2, 6.4, 12.8 and 25.6 nmol⋅min-1 with the infusion rate doubled every 30 min and stopped at
196 min. The break at 90 – 96 min was due to changing the syringe. The solid gray line represents
the fit of the pool/precursor model to the same individual. B) Study 2 - A constant rate of 25.6
nmol⋅min-1 given over 30 min. C) Study 3 - Two consecutive infusions of 32 and 64 nmol⋅min-1. The
infusion rate was increased at 73 min and the total time of infusion 104 min. D) Study 4 - Infusion
rate increased stepwise from 0 to 13 nmol⋅min-1 over 30 min, held constant at 13 nmol⋅min-1 over 30
min, and decreased stepwise from 13 nmol⋅min-1 to 0 over 30 min.

28 % rise above baseline, respectively. In study 1, dosing was stopped for
about 5 min between infusions 3 and 4. This brief interruption resulted
in an increase in average plasma NEFA concentration from 0.36 to 0.57
mmol⋅l-1. There was a slight indication of development of tolerance in
study 1, evidenced as an increase in plasma NEFA concentrations during
several of the 30 min infusion periods (Fig. 5 and 6A).
The feedback model with biophase kinetics was fitted to individual
response-time data from the different studies. The average final parameter estimates and their precision (average relative standard deviation
CV%) are shown for study 1 in Table 3. The model-predicted NEFA concentrations were consistent with the experimental data, the precision of
the estimates was high for all parameters, and they showed low correlation. The range of each estimate from applying the model to all four studies is shown in brackets in Table 3. Since no plasma concentrations of
NiAc were available from the rat experiments, the applicability of the twocompartment model with parallel first-order and Michaelis-Menten elim260
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ination proposed by Iwaki et al. (1996) was evaluated. However, as systematic deviations between fitted and experimental NEFA response-time
data were observed, and biased and imprecise parameter estimates were
calculated, this disabled its further use as a ‘driver’ of the NEFA responsetime data.
TABLE 3. Initial and final estimates of the turnover model parameters ± CV %*
Parameter

R0 (mmol⋅l-1)
kout (min-1)
ktol (min-1)
ID50 (µmol)
n
ke (min-1)
Ka (min-1)

Current Investigation – Study 1 (n = 7)

Literature data***

Initial estimate

Final estimate ± CV % (Range)**

Final estimate ± CV %

0.6
0.1
0.05
0.03
2
0.2
0.01

0.55 ± 3.6 (0.41 – 0.55)
0.30 ± 31 (0.14 – 0.35)
0.079 ± 27 (0.023 – 0.079)
0.0065 ± 31 (0.0065 – 0.058)
1.4 ± 9.2 (1.4 – 3.7)
0.44 ± 18 (0.21 – 0.44)

0.50 ± 0.96
0.16 ± 12.0
0.035 ± 18.6
0.12 ± 3.8
6.7 ± 16.6
0.021 ± 2.1

*Final estimates from study 1 are presented as mean ± mean CV%. Here the CV% is the precision
of the parameter estimate calculated as (SD/mean)·100 in WinNonlin
** Range from all studies
*** From analysis of data reported by Carballo-Jane et al. (2007)

The present analysis of NiAc-induced plasma NEFA responses predicts a t1/2 ke of 2 min (2 – 3 min) ± 18 %, a t1/2 kout of 3 min (2 – 5 min) ±
31 % and a t1/2 ktol for tolerance development of 9 min (9 – 30 min) ± 27
%. Initially, maximum efficacy Imax (Eq. 3) was used as a model parameter.
However, as it was estimated to very close to unity, we then assumed complete inhibition of the plasma NEFA turnover rate at a high NiAc concentration, and set Imax to unity.
The ID50 value was translated into an IC50 value according to Equation
16, using an estimate of the volume of distribution of NiAc based on rat
data (0.17 l). IC50 was estimated to 0.038 µmol⋅l-1. The concentrationresponse relationship between NiAc and NEFA at equilibrium, was then
simulated by means of Equation 17 (Fig. 7) with feedback present. The
corresponding relationship for a non-tolerant system (i.e. without feedback, Eq. 18) is shown in Fig. 7 for comparison. To reduce plasma NEFA
concentrations to about 0.1 mmol⋅l-1, NiAc concentrations of 0.1 and 0.5
µM are needed for the non-tolerant and tolerant system, respectively.
The NEFA response-time data were also analyzed by means of a
pool/precursor model (Licko and Ekblad 1992, Bauer et al. 1994, Sharma
et al. 1998). Since the basic pool/precursor model gives an area under the
rebound curve that is per definition equal to the area under the response
curve, it failed to acceptably mimic the experimental NEFA response-time
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FIGURE 7. Simulated steady state plasma NiAc concentration vs. response (plasma NEFA concentrations). The solid line uses the final estimates from study 1 of R0 (0.55 mmol⋅l-1) and n (1.4), and
the approximated value of IC50 (0.038 µmol⋅l-1) with tolerance included (Eq. 17). The lefthand
dashed line uses the same estimates but without tolerance included in the model (Eq. 18). The righthand dashed line represents the estimates from Carballo-Jane et al. (2007), with inclusion of a physiological lower limit (Rlow, Eq.19) of 0.063 mmol⋅l-1.

data (Fig. 6A), resulting in biased and imprecise parameter estimates and
was therefore abandoned in the subsequent analysis.
Analysis of literature data (Carballo-Jane et al. 2007)

The model-predicted responses were consistent with the experimental data as shown in Fig. 8. The final parameter estimates and their precision (CV %) are shown in Table 3. The model predicted equilibrium relationship between NiAc and NEFA response is shown in Fig. 7. When fitting the data of Carballo-Jane et al. (2007), the elimination rate constant
ke of the biophase compartment was fixed to a constant value of 0.4 min-1,
obtained from the analysis of our own data following multiple intravenous infusion of NiAc. The analysis predicts a t1/2 kout of 4 min ± 12 %
and a t1/2 ktol for tolerance development of 20 min ± 19 %. The absorption
rate constant Ka following oral administration was estimated to a twentieth (0.021 min-1) of the elimination rate constant ke of the biophase
model, with a half-life of ~ 35 min, which indicates absorption rate limited elimination of NiAc. We also applied the two-compartment disposition
model with parallel first-order and Michaelis-Menten elimination by
Iwaki et al. (1996), as a ‘driver’ of the NEFA response-time data. Again, systematic deviations between fitted and experimental NEFA response-time
data and biased and imprecise parameter estimates were seen.
262
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FIGURE 8. Data from a study performed by Carballo-Jane et al. (2007). Observed (symbols) and
predicted (solid line) response (plasma NEFA concentrations, mmol⋅l-1)–time following oral administration of 3 mg⋅kg-1 (I), 10 mg⋅kg-1 (G), 100 mg⋅kg-1 (M) and 300 mg⋅kg-1 (L) of NiAc to male
Sprague Dawley rats. At time t = 0 min and t = 20 min all observed data points are superimposed. The
baseline response of 100 % was fixed to 0.5 mmol⋅l-1 for comparison with the in-house experiments
(see Fig. 6).

DISCUSSION

NiAc treatment simultaneously decreases LDL and increases HDL
cholesterol levels (Offermanns 2006), and decreases cardiovascular
events such as myocardial infarction and death (Canner et al. 1986,
Carlson and Rosenhamer 1988, Carlson 2005). While other drugs such as
statins produce similar effects, it may be the drug of first choice if tolerated by the patient. However, use of NiAc is limited because it is associated with cutaneous flushing and a substantial rebound of plasma NEFA
concentrations above predose baseline levels. For this reason, there is a
need for better understanding of the mechanism behind the complex
regulation of plasma NEFA metabolism and its feedback mechanisms (e.g.
insulin). Thorough quantitative analysis of the time-course of the plasma
NEFA response to NiAc provides one source of important information
about this system.
In the present work, a one-compartment pharmacokinetic model was
developed to describe the concentration time-course of NiAc in guinea
pigs. The plasma kinetics of NiAc was rapid, with a clearance of 70
ml⋅min-1⋅kg-1 and a low volume of distribution of 0.15 l·kg-1, resulting in a
half-life of about 1.5 min. A two-compartment model was also fitted to the
concentration-time data but the parameter precision was low, and the
contribution of the terminal phase to the overall assessment of clearance
and volume terms was negligible because the plasma concentration fell
more than two orders of magnitude within the first 15 min after stopping
263
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infusion. However, since NiAc exhibits nonlinear pharmacokinetics in
rats at higher concentrations (Iwaki et al. 1996), a multi-compartment
approach may be necessary to obtain a complete description of NiAc disposition in guinea pig plasma.
A pharmacodynamic feedback model was developed to characterize
the turnover of plasma NEFA concentrations in rats following administration of NiAc using different infusion regimens. Regulating processes,
which inversely affect the formation of plasma NEFA, are included as a
single unit (moderator M) in the pharmacodynamic model. The aim of
developing this mechanistic turnover model is to provide a means for
obtaining quantitative information about factors that determine the timecourse of the plasma NEFA response following acute dosing of NiAc. In
short, this model will serve as a preclinical tool for analyzing and simulating drug-induced changes in plasma NEFA concentrations after treatment with, for example, NiAc or NiAc analogues.
An important aspect of physiological systems is that one or more biomarkers can be studied under varying conditions. For example, a biomarker of interest (e.g. glucose) can be administered and its disposition
measured after different rates, routes and modes of administration.
Alternatively, the system can be perturbed by something (e.g. insulin) that
regulates the biomarker of interest (e.g. glucose). The biomarker used in
this investigation was plasma NEFA concentrations, which provide a measure of a conglomerate of fatty acids with varying chain lengths targeted
by treatment with NiAc (Frape et al. 2000). Because the mechanism of
NiAc action is via inhibition of the release of NEFA into plasma, it is
preferable to study the turnover of the plasma NEFA pool by varying the
rate of NiAc input and the extent of NiAc exposure. To do this, we have
used a multiple infusion technique, varying the rate and duration of dosing with NiAc. The NEFA datasets analyzed in this study were originally
designed to qualitatively assess the behavior of plasma NEFA concentrations after different NiAc provocations, rather than for modeling purposes. As a result, the sampling schedule was intended to detect the maximum and minimum response to NiAc, and to demonstrate the rebound
phenomenon. In view of this, the data collected were more exploratory
than optimal in the context of parameter identification.
In spite of the above reservations, however, the experiments display
some interesting features of plasma NEFA turnover when analyzed quantitatively using the regression model (Fig. 2), and highlight some of the pros
and cons of the proposed turnover model. We will challenge some of these
(e.g. the observation that the turnover of plasma NEFA is a more rapid
process than that of the regulating processes M) in future experiments.
Other findings of particular interest are the almost complete inhibition of
NEFA by NiAc and the rapid and pronounced rebound of plasma NEFA
concentrations after cessation of NiAc infusion. The primary reason NiAc
264
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is a suitable compound for studying tolerance and rebound of NEFA is its
rapid plasma kinetics. With a NiAc plasma concentration half-life of only
1–3 min, it is possible to affect multiple changes in NiAc infusion rates and
steady-state concentrations all with rapid washout profiles, in turn optimizing conditions for rebound of plasma NEFA concentrations.
The most common approach in PK/PD modeling is to let the plasma
concentration time-course drive the drug mechanism function acting on
the production or loss term of the turnover model. Three different
approaches were used to resolve the lack of good NiAc exposure profiles
used to ‘drive’ the pharmacodynamic model, A) High-dose pharmacokinetic data in male Wistar rats were initially used to predict the exposure
to low-dose NiAc in male Sprague Dawely rats used for NEFA modeling,
B) Pharmacokinetic data from the presented guinea pig studies were
scaled allometrically to the Sprague Dawely rats. Both approaches, A)
and B), failed to successfully ‘drive’ the pharmacodynamic model fitted
to NEFA plasma concentrations. This may be due to the fact that highdose data poorly predicts the time-course of low-dose data particularly
when one extrapolates from Wistar to Sprague Dawely rats or from conscious to anaesthetized animals, or scaling from one species (guinea pig)
to another (rat). In the absence of measured plasma concentrations or
when there is scanty information about exposure-time relationships, a
parametric biophase model has been proposed, linking input of dose to
drug mechanisms of action (Smolen 1971, Gabrielsson et al. 2000).
Although the biophase kinetic model may not exactly represent the plasma kinetics of NiAc, it still contributes to the estimation of the system
parameters (e.g. kout, ktol) and drug parameter ID50, which in turn can be
converted to an IC50 value using the volume of distribution of NiAc.
Approach C) resulted in high consistency between experimental and
model predicted NEFA data.
Using a multiple intravenous infusion technique, NiAc was shown to
reduce plasma NEFA concentrations in rats by 67-86 % below baseline,
followed by a post-infusion rebound of 28-150 % above predose baseline.
It was assumed that the formation of plasma NEFA could be totally
blocked by high exposure to NiAc (Imax equal to 1). Indeed, when Imax was
included in the model the estimate approached unity, supporting the
assumption of total blockage. Although reasonably high doses of NiAc
were given, plasma NEFA concentrations did not decline to zero, which
might indicate a physiological minimum below which plasma NEFA concentrations remain unaffected by NiAc. While such a physiological limit
was included in the model according to Yao et al. (2006), the estimated
minimum was negligible.
The ranges of all final parameters estimates are shown in brackets in
Table 3. It can be noted that the final parameter estimates from study 1 fall
either on the lower or upper boundary for several of the parameters. We
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believe that the challenging design of the multiple consecutive infusions
regimen (n=7) may reveal a more correct behavior of the system. Studies
2-4 are more of an exploratory nature, with respect to number of animals
per design (n=1), dose levels, duration of dosing and sampling schedule,
and therefore less information rich. This can give biased results.
The same total dose of NiAc was given in studies 2 and 4, but with different dosing regimens. Approximately the same reduction in plasma
NEFA concentrations below baseline was seen in both studies (78 and 67
%, respectively) but the peak of the rebound was significantly lower in
study 4 (71 % increase above baseline in study 2 compared to 28 % in
study 4) where the infusion rate was increased and decreased in a stepwise manner. Due to the slow decrease in infusion rate, the concentration
of NiAc declined gradually, with the result that rebound was less pronounced. It is possible, therefore, that by prolonging the gradual decline
in plasma exposure to NiAc the rebound may be abolished. This will be
evaluated in future studies. It is also possible that a compound with a
longer terminal half-life might have the same inhibitory effect on the
rebound, as does the more prolonged exposure to NiAc.
In the present series of experiments, there was little evidence of the
development of tolerance apart from the slight increase in plasma NEFA
concentrations during all but the last 30 min infusion period in study 1
(Fig. 6A). In our data, the rebound is considerably easier to detect than
the tolerance during NiAc exposure. Since the rebound occurs as a result
of a counteracting mechanism to the NEFA-lowering effect, it may therefore be a strong indicator of tolerance development. However, the time
scale of developing tolerance might differ from (be slower than) that of
the primary response (t1/2 kout) (Gabrielsson and Peletier 2008). If so,
extended drug exposure might be needed to capture the tolerance
experimentally. As the t1/2 ktol parameter serves as an indicator of the tolerance time scale, it can be used for guidance in experimental design.
The present analysis of NiAc-induced plasma NEFA responses predicts a
t1/2 kout of 2 min (2 – 5 min) and a t1/2 ktol for tolerance development of 9
min (9 – 30 min). Although there is no generic schedule guiding the
design of experiments aimed at capturing tolerance development, multiple provocations for at least 3–4 · t1/2 ktol, coupled to washout dynamics
with sufficient baseline data, are commonly needed (Gabrielsson and
Peletier 2008).
By modeling the complete NEFA response time-course, we obtained
parameter estimates that characterized the concentration-response relationship at equilibrium. As shown in Fig. 7, this relationship was not particularly steep regardless of whether or not we included feedback in the
model. This contrasts with the data analyzed from Carballo-Jane et al.
(2007). Those authors did not utilize a quantitative model, and the resolution of their exposure-time and response-time data were slightly lower.
266
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For this reason we fitted our model to a digitized set of Carballo-Jane et
al. (2007) data. The conclusions from this quantitative analysis are consistent with those from our multiple NiAc infusions, and most parameters
were in the same range; the exceptions were the potency ID50 and the Hill
factor n, which were significantly higher for the Carballo-Jane et al. (2007)
data. These differences may be due to differences in the experimental set
up, including the use of anesthesia, sampling route, vehicle, dose range,
and in the kinetics. According to Kanaris et al. (1975), Renauld and
Sverdlik (1975) and Reyes Toso et al. (1993) the metabolism of NEFA may
be perturbed by barbiturate anesthesia, so it is noteworthy that CarballoJane et al. (2007) used conscious rats while our rats were anaesthetized
with Na-thiobutabarbital. Furthermore, venous blood samples were used
by Carballo-Jane et al. (2007) whereas we collected arterial blood samples.
In Carballo-Jane et al. (2007), the vehicle was 0.5 % methylcellulose and
the NiAc dose range 3 to 300 mg·kg-1 (24-2440 µmol·kg-1), whereas in our
experiments the vehicle was 0.9 % NaCl and the dose range 0.5 to 1 mg·kg1
(4-8 µmol·kg-1). If the bioavailability is overrated, the amount of drug giving rise to the reduction in plasma NEFA concentrations would be smaller and the potency would increase. The higher value of n for the CarballoJane et al. (2007) data is indicative of a steeper dose-response relationship
(Fig. 7) than in our study. Finally, in the analysis, the pharmacokinetics was
assumed to be linear, although Iwaki et al. (1996) demonstrated capacitylimited disposition of NiAc in rats within the 2-45 mg·kg-1 (16.3-370
µmol·kg-1) NiAc dose range with Km ~ 40 µM. The Carballo-Jane et al.
(2007) doses fall beyond this dose interval (3-300 mg·kg-1). We assumed a
first-order elimination term from the biophase compartment, which may
confound the estimation of IC50 (ID50) and the n terms.
Our data did not support the presence of a physiological lower limit.
However, the highest dose administered in Carballo-Jane et al. (2007) was
approximately 300 times higher than our highest dose but revealed such
a limit. To be able to fit the model to the Carballo-Jane et al. (2007) data
the physiological limit had to be included.
This study is the first in a series examining the pharmacodynamics of
plasma NEFA concentrations after multiple NiAc provocations, and it will
be expanded by experiments designed to further explore NEFA turnover.
These will include measurements of exposure to NiAc and its impact on
plasma NEFA concentrations in the same animal under varying experimental conditions.
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